Intestinal Dysbiosis and its Relationship with Cardiovascular Diseases

Authors

Keywords:

dysbiosis, gut microbiota, microbiome, atherosclerosis, cardiovascular disease.

Abstract

Introduction: Intestinal dysbiosis or alteration in the composition of the digestive microbiota is related to the appearance of congenital and acquired cardiovascular diseases that respond to a maintained inflammatory state. Objective: To update knowledge about the relationship between intestinal dysbiosis and chronic non-communicable cardiovascular diseases, based on the literature review. Methods: A documentary review was carried out of the national and international bibliography, published in the last five years in English and Spanish, on intestinal dysbiosis and cardiovascular diseases. The Google Scholar search engine was used and free access articles were consulted in PubMed, SciELO, Lilacs, Cumed and Hinari databases, according to the health sciences descriptors. Results: Intestinal dysbiosis is closely related to cardiovascular effects caused by the activation of inflammation metabolites released by stimulation of the intestine-heart axis. Conclusions: The prevention of cardiovascular diseases can be modulated through healthy and safe nutrition. Keywords: dysbiosis; gut microbiota; microbiome; atherosclerosis; cardiovascular disease.

Downloads

Download data is not yet available.

References

1. Álvarez M, Cortés MV, Quirós LM. El impacto de la microbiota en la enfermedad cardiovascular. Rev Méd Sinergia. 2021;6(2). DOI: https://doi.org/10.31434/rms.v6i2.643

2. Heintz-Buschart A, Wilmes P. Human Gut Microbiome: Function Matters. Trends Microbiol. 2018;26(7):563-74. DOI: https://doi.org/10.1016/j.tim.2017.11.002

3. Merino JA, Taracena S, Díaz EJ, Rodríguez FL. Microbiota intestinal: “el órgano olvidado”. Acta Méd. 2021;19(1):92-100. DOI: https://doi.org/10.35366/98577

4. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369-79. DOI: https://doi.org/10.1056/NEJMra1600266

5. Theis KR, Romero R, Motomura K, Galaz J, Winters AD, Pacora P, et al. Microbial burden and inflammasome activation in amniotic fluid of patients with preterm prelabor rupture of membranes. J Perinat Med. 2020;48(2):115-31. DOI: https://doi.org/10.1515/jpm-2019-0398

6. Ortiz M, Harris PR. Importancia de la ruta de parto en la adquisición del microbioma en la temprana infancia. Rev Chil Pediatr. 2019;90(5):476-7. DOI: https://doi.org/10.32641/rchped.v90i5.1236

7. Ramírez MLP, López GT, Varela MA. Antibióticos y disbiosis. Enf Inf Microbiol. 2021 [acceso 14/11/2023];41(3):118-22. Disponible en: https://www.medigraphic.com/pdfs/micro/ei-2021/ei213f.pdf

8. Castañeda C. Microbiota intestinal y salud infantil. Revista Cubana de Pediatría. 2018 [acceso 11/12/2023];90(1):94-110. Disponible en: http://scielo.sld.cu/pdf/ped/v90n1/ped10118.pdf/

9. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1). DOI: https://doi.org/10.3390/microorganisms7010014

10. Álvarez J, Fernández JM, Guarner F, Gueimonde M, Rodríguez JM, Saenz M, et al. Microbiota intestinal y salud. Gastroenterol Hematol. 2021;44(7):519-35. DOI: https://doi.org/10.1016/j.gastrohep.2021.01.009

11. Kitai T, Wilson Tang WH. Impacto de la microbiota intestinal en la enfermedad cardiovascular. Rev Esp Cardiol. 2017;70(10):799-800. DOI: https://doi.org/10.1016/j.recesp.2017.04.003

12. Li H, Zhang X, Pan D, Liu Y, Yan X, Tang Y, et al. Dysbiosis characteristics of gut microbiota in cerebral infarction patients. Transl Neurosci. 2020;11(1):124-33. DOI: https://doi.org/10.1515/tnsci-2020-0117

13. Pietiäinen M, Liljestrand JM, Kopra E, Pussinen PJ. Mediators between oral dysbiosis and cardiovascular diseases. Eur J Oral Sci. 2018;126(1):26-36. DOI: https://doi.org/10.1111/eos.12423

14. Carrillo-Salinas FJ, Anastasiou M, Ngwenyama N, Kaur K, Tai A, Smolgovsky SA, et al. Gut dysbiosis induced by cardiac pressure overload enhances adverse cardiac remodeling in a T cell-dependent manner. Gut Microbes. 2020;12(1). DOI: https://doi.org/10.1080/19490976.2020.1823801

15. García-Ríos A, Camargo A, Perez-Jimenez F, Perez-Martinez P. Microbiota intestinal: ¿un nuevo protagonista en el riesgo de enfermedad cardiovascular? Clin Investig Arterioscler. 2019;(31)4:178-85. DOI: https://doi.org/10.1016/j.arteri.2018.11.003

16. Zhen J, Zhou Z, He M, Han HX, Lv EH, Wen PB, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 2023;14. DOI: https://doi.org/.3389/fendo.2023.1085041

17. Krüger-Genge A, Jung F, Hufert F, Jung EM, Küpper JH, Storsberg J. Effects of gut microbial metabolite trimethylamine N-oxide (TMAO) on platelets and endothelial cells. Clin Hemorheol Microcirc. 2020;76(2):309-16. DOI: https://doi.org/10.3233/CH-209206

18. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010;91(3):535-46. DOI: https://doi.org/10.3945/ajcn.2009.27725

19. Eshghjoo S, Jayaraman A, Sun Y, Alaniz RC. Microbiota-mediated immune regulation in atherosclerosis. Molecules. 2021;26(1). DOI: https://doi.org/10.3390/molecules26010179

20. Shanks J, Ramchandra R. Angiotensin II and the cardiac parasympathetic nervous system in hypertension. Int J Mol Sci. 2021;22(22). DOI: https://doi.org/10.3390/ijms222212305

21. Férez SM, Márquez MF, Peña MA, Ocaranza R, Peña E, Eid G. Daño miocárdico por reperfusión. Rev Esp Cardiol. 2004;57(1):9-21. DOI: https://doi.org/10.1157/13067415

22. Agudelo GM, Giraldo NA, Barrera CJ, Valdés BE. Microbiota intestinal y ácidos grasos de cadena corta en pacientes críticos. Perspectivas en Nutrición Humana. 2017;18(2):205-22. DOI: https://doi.org/10.17533/udea.penh.v18n2a06

23. Maciezrynski LE. N-óxido de trimetilamina y su relación con la enfermedad coronaria. Rev CONAREC. 2018 [acceso 03/04/2021];34(143):28-36. Disponible en: https://adm.meducatium.com.ar/contenido/articulos/15500280036_1083/pdf/15500280036.pdf

24. Dai Y, Tian Q, Si J, Sun Z, Shali S, Xu L, et al. Circulating metabolites from the choline pathway and acute coronary syndromes in a Chinese case-control study. Nutr Metab (Lond). 2020;17. DOI: https://doi.org/.10.1186/s12986-020-00460-0

25. Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102-12. DOI: https://doi.org/10.1080/0886022X.2020.1864404

26. Gómez-López A. Microbioma, salud y enfermedad: probióticos, prebióticos y simbióticos. Biomédica. 2019 [acceso 14/11/2023];39(4):617-21. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31860173

Published

2024-09-07

How to Cite

1.
Mena Miranda VR. Intestinal Dysbiosis and its Relationship with Cardiovascular Diseases. Rev Cubana Pediatría [Internet]. 2024 Sep. 7 [cited 2025 Jul. 1];96. Available from: https://revpediatria.sld.cu/index.php/ped/article/view/5576